Premium
COVID‐19 in hospitalized HIV‐positive and HIV‐negative patients: A matched study
Author(s) -
Díez Cristina,
Del RomeroRaposo Jorge,
Mican Rafael,
López Juan C.,
Blanco José R.,
Calzado Sonia,
Samperiz Gloria,
Portilla Joaquín,
GarcíaFraile Lucio J.,
Gutiérrez Félix,
GómezSirvent Juan L.,
SuárezGarcía Inés,
Amador Concha,
Novella María,
Arribas Jose R.,
Moreno Santiago,
GonzálezGarcía Juan,
Jarrín Inmaculada,
Berenguer Juan
Publication year - 2021
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.13145
Subject(s) - medicine , cohort , retrospective cohort study , covid-19 , cohort study , human immunodeficiency virus (hiv) , pandemic , antiretroviral therapy , young adult , viral load , pediatrics , immunology , disease , infectious disease (medical specialty)
Objectives We compared the characteristics and clinical outcomes of hospitalized individuals with COVID‐19 with [people with HIV (PWH)] and without (non‐PWH) HIV co‐infection in Spain during the first wave of the pandemic. Methods This was a retrospective matched cohort study. People with HIV were identified by reviewing clinical records and laboratory registries of 10 922 patients in active‐follow‐up within the Spanish HIV Research Network (CoRIS) up to 30 June 2020. Each hospitalized PWH was matched with five non‐PWH of the same age and sex randomly selected from COVID‐19@Spain, a multicentre cohort of 4035 patients hospitalized with confirmed COVID‐19. The main outcome was all‐cause in‐hospital mortality. Results Forty‐five PWH with PCR‐confirmed COVID‐19 were identified in CoRIS, 21 of whom were hospitalized. A total of 105 age/sex‐matched controls were selected from the COVID‐19@Spain cohort. The median age in both groups was 53 (Q1–Q3, 46–56) years, and 90.5% were men. In PWH, 19.1% were injecting drug users, 95.2% were on antiretroviral therapy, 94.4% had HIV‐RNA < 50 copies/mL, and the median (Q1–Q3) CD4 count was 595 (349–798) cells/μL. No statistically significant differences were found between PWH and non‐PWH in number of comorbidities, presenting signs and symptoms, laboratory parameters, radiology findings and severity scores on admission. Corticosteroids were administered to 33.3% and 27.4% of PWH and non‐PWH, respectively ( P = 0.580). Deaths during admission were documented in two (9.5%) PWH and 12 (11.4%) non‐PWH ( P = 0.800). Conclusions Our findings suggest that well‐controlled HIV infection does not modify the clinical presentation or worsen clinical outcomes of COVID‐19 hospitalization.